Alarm signals generated at inflammatory foci reach the vascular lumen to attract immune cells towards the affected tissue. Different leucocyte subsets decipher and integrate these complex signals in order to make adequate decisions for their migration towards the inflamed tissue. Soluble cues (cytokines and chemokines) and membrane receptors in both endothelium and leucocytes orchestrate the coordinated recruitment of specific inflammatory cell subsets. All these molecules are spatio-temporally organized in specialized structures at the luminal side of endothelium and the leucocyte membrane or are generated as chemical gradients in the damaged tissue. Thus, the repertoire of chemokines and their receptors as well as adhesion molecules expressed by each leucocyte subset determine their recruitment for participation in specific inflammatory pathologies. Whenever inflammatory signals are altered or misprocessed, inflammation can become chronic, causing extensive tissue damage. To combat chronic inflammation and autoimmune diseases, novel therapeutic strategies attempt to silence the predominant signals in each inflammatory scenario. In this review, we provide a general overview of all these aspects related to the molecular regulation of leucocyte guidance in inflammatory responses.
Inflammation is a hallmark of a multitude of severe and prevalent diseases, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn's disease, and asthma. In this regard, it will be of critical importance to limit the efflux of specific effector leucocytes to sites of chronic inflammation. Therefore, unravelling the complexity of leucocyte guidance during inflammation in the search for novel and effective therapies is a major goal in vascular biology and immunology. Thus, soluble factors such as inflammatory cytokines, chemokines, and chemoattractants as well as membrane adhesion receptors constitute good therapeutic targets, since they are fundamental to the coordinated selection and recruitment of leucocytes to inflammatory foci ( Figure 1 ).
Cytokines, chemoattractants, chemokines, and chemokine receptors
The process of leucocyte extravasation is influenced by pro-inflammatory cytokines (IL-1a and b, IL-6, and TNF-a, among others) and classical chemoattractants for myeloid cells (fMLP, C5a, LTB4, and PAF) produced locally at the inflammatory focus. In fact, the selective secretion of certain chemokines and the up-regulation of expression of endothelial adhesion molecules induced by specific cytokines contribute to delineate the subsets of leucocytes that are recruited during different phases of an inflammatory response. In addition, cytokines and chemoattractants activate leucocytes to migrate using specific adhesion receptors. 1, 2 Many different resident and infiltrating cell types at the inflammatory focus are able to release the chemotactic cytokines called chemokines, which upon reaching the luminal surface of endothelium, elicit leucocyte activation, and migration. In response to pro-inflammatory stimuli such as TNF-a, IL-1b, IFN-g, thrombin, or LPS, endothelial cells from various vascular beds are able to synthesize different chemokines such as CXCL8, CCL-2, CXCL10, CXCL12, CCL5, or CXCL1. 3 In addition, neutrophils, central players in acute inflammatory phenomena, secrete chemoattractants to recruit other leucocyte subtypes in later stages of the inflammatory response. 4 Endothelial cells produce and transcytose external chemokines, exposing them mainly on glycosaminoglycans (GAGs) 5 and on the Duffy antigen/receptor for chemokines, 6 which are highly enriched † Both authors contribute equally to this work.
Figure 1
Molecular cues guiding leucocyte extravasation towards inflammation. When an inflammatory focus appears, there are cytokines and chemokines locally released that reach the surrounding endothelium, which in turn becomes activated. Endothelial activation implies the luminal expression of adhesion receptors involved in subsequent steps of the leucocyte adhesion cascade. During the step 1 (tethering and rolling), freeflowing leucocytes establish labile contacts with activated endothelial cells, which are dependent on selectins and their ligands. Rolling allows leucocytes to scan the endothelial surface in the search of stimuli such as GAG-immobilized chemokines. These molecules trigger signals through leucocyte chemokine receptors, which predispose leucocyte integrins to bind endothelial ligands. Thus, leucocytes become firmly adhered to the endothelium and begin to crawl towards a suitable place for transmigration (step 2). Both processes mainly rely on the interaction of integrins (VLA-4, a4b7, LFA-1, and Mac-1) with their endothelial ligands (VCAM-1, ICAM-1, and ICAM-2, among others, which are organized in tetraspanin-enriched microdomains). During the transition from step 1 to step 2, leucocytes experiment a drastic morphological change from round to polarized pro-migratory shape. L-selectin, CD44, ICAM-3, ICAM-1, and others localized at the leucocyte rear pole (uropod), whereas integrins and chemokine receptors redistribute to the contact area with the endothelium and the leading edge. On the endothelial side, there is also an actin-based structural reorganization which gives rise to a docking structure (microvilli highlighted in grey) around the adhered leucocyte to prevent its detachment while withstanding stringent flow conditions. Step 3 (transendothelial migration) is illustrated in the figure as a paracellular passage of a leucocyte in between two adjacent endothelial cells. Then, leucocytes have to traverse the endothelial basement membrane and continue their journey across the extracellular matrix following the chemotactic gradient towards the inflammatory focus illustrated herein as pathogens (step 4).
in apical endothelial microvilli. Thus, immobilization of chemokines prevents dispersion of the chemotactic signal, facilitates their availability for recognition by adherent leucocytes, and prevents desensitization of free-flowing leucocytes by soluble chemokines. 7 The primary role of endothelium-immobilized chemokines is to promote the transition of leucocytes from selectin-mediated tethering and rolling to integrin-mediated firm attachment and spreading by inducing the activation of leucocyte integrins via chemokine receptors. 8 Chemokine receptors are G protein-coupled receptors bound to Gai/Gao and present in leucocytes to sense chemokine signals and transduce them to integrins. Each specific leucocyte subset is characterized by a defined pattern of surface-expressed chemokine receptors that determine its ability to migrate to different tissues to exert its immune functions. 9 The chemokine -chemokine receptor system determines that cell traffic during inflammatory responses occurs in the proper spatial and temporal fashion. Disturbances of this system can lead to a deleterious chronic inflammatory condition. In this regard, an altered pattern of expression of the GAGs detected on the luminal surface of endothelium has been observed in several pathological and physiological situations, such as atherosclerosis, inflammatory bowel disease, and wound healing. 10, 11 Besides, an inadequate desensitization of chemokine receptors or an altered clearance of chemokines at the later stages of inflammation can convert acute into chronic inflammation. 7 
Adhesion receptors
Extravasation during inflammation occurs preferentially at postcapillary venules. Once an inflammatory focus arises, endothelial cells become activated by soluble factors and greatly increase the content of adhesion receptors on their luminal surface, making them sticky for free-flowing leucocytes. Activated endothelium expresses E-and P-selectins (necessary to initiate leucocyte capture by tethering and rolling) as well as several integrin ligands such as VCAM-1, ICAM-1, and ICAM-2 (differentially involved in firm adhesion, crawling, paracellular, and transcellular migration), and PECAM-1, JAM proteins, ESAM, CD99, etc., which act during paracellular transmigration. 12, 13 E-and P-selectins interact with L-selectin and PSGL-1 expressed by leucocytes, as well as with other specific ligands such as ESL-1 and CD44 in the case of E-selectin.
14,15 VCAM-1 is the endothelial ligand for the integrins VLA-4 and a4b7, while ICAM-1 and ICAM-2 bind LFA-1 and the myeloid integrin Mac-1. 16 MadCAM is a major ligand for the integrin a4b7, driving leucocyte migration to the gut, and also interacts with L-selectin. PECAM-1 and JAM proteins can interact with themselves or heterotypically with integrins. 17, 18 Under homeostatic conditions, leucocyte integrins are maintained in a bent inactive conformation. Upon contact with activated endothelium, chemokine receptors bind the chemokines localized on the endothelial surface and generate signals that trigger leucocyte integrins to change into an extended conformation, predisposing them to bind their ligands and adopt their high affinity conformation. 19 Some leucocyte subsets (such as neutrophils and certain lymphocyte subsets) use preferentially LFA-1 during firm adhesion, whereas VLA-4 is the predominant integrin in monocytes and also in lymphoblasts migrating in inflamed vasculature from blood brain barrier. 20 Thus, the differential usage of defined pairs of adhesion receptors by inflammatory cells is another point of control in leucocyte recruitment into inflammatory foci.
Spatiotemporal organization of adhesion molecules in endothelial cell-leucocyte interplay during inflammation
To accomplish efficient intercellular communication between leucocytes and activated endothelium, it is crucial that the molecules involved are properly displayed in time and space. To ensure this, both cellular types have developed specialized structures that organize and cluster receptors to improve their adhesiveness.
Endothelial structures
The spatial organization of endothelial adhesion receptors was initially studied by transmission electron microscospy, which showed that most of them are enriched at apical microvilli. 21 A detailed nanoscopic analysis of endothelial receptor distribution has revealed that the apical endothelial surface displays a complex organization of adhesive platforms enriched in tetraspanins and containing selectins and multiple adhesion molecules of the Ig superfamily such as VCAM-1, ICAM-1, ICAM-2, PECAM-1, and JAM molecules 22 (see also
Barreiro et al., unpublished results). Tetraspanins, a family of proteins containing four membrane-spanning domains, are able to interact simultaneously with other tetraspanins and with transmembrane receptors to form platforms in which receptors are precisely clustered. 23 These platforms appear to ensure the proper spatiotemporal clustering of adhesion receptors that might be needed in subsequent steps of the adhesion cascade of leucocytes, increasing their surface density and availability and thereby increasing the efficiency of extravasation. These endothelial adhesive platforms are preformed functional units at the apical membrane of activated endothelium that coalesce around adherent leucocytes to form a three-dimensional actin-based structure ('docking structure' or 'transmigratory cup') that prevents leucocyte detachment and stabilizes their firm adhesion to endothelium. 24, 25 In this regard, we have found that adhesion receptors, either uncoupled or coupled to their leucocyte ligands, are recruited into these cell membrane structures in a cytoskeleton-independent but tetraspanin-dependent manner. 22 Endothelial docking structures also contain structural proteins such as ezrin, moesin, alpha-actinin, vinculin, paxillin, talin, and VASP, and are regulated by Rho/ROCK signalling and second messengers as PIP 2 . 24 These endothelial structures are dynamic, and surround the leucocyte as it crawls towards a suitable place for transmigration. Leucocyte extravasation, or diapedesis, occurs more frequently through a paracellular pathway, but can also follow a transcellular route. During paracellular transmigration, ICAM-1 and JAM-A relocalize through interaction with LFA-1, to form a ring-shaped cluster around the leucocyte. 26 Transcellular migration requires membrane fusion, regulated by Ca 2þ and SNAREcontaining complexes, and the supply of additional membrane by the vacuole-vesicular organelles for the formation of the transcellular pore. 27 ICAM-1 along with caveolin-1 are translocated towards the transcellular pore, 28 moving then towards the basal endothelial membrane. In addition, the intermediate filament protein vimentin has been reported to play an important role in the transcellular route. 29 Although all these data come from in vitro approaches, it has been recently detected the existence of dome-shaped endothelial structures in vivo, which cover neutrophils during their transcellular and paracellular migration. 30 These observations indicate that endothelial docking structures might become domes that completely engulf the leucocytes on the luminal face of the endothelium, thereby allowing the disassembly of the basolateral membrane without compromising the endothelial barrier function.
Leucocyte structures
Leucocytes show dramatic changes in their morphology during the process of extravasation, from a round to a polarized shape. 31 During the first stages of leucocyte-endothelial interaction, L-selectin and PSGL-1 are the main leucocyte receptors involved, and are exposed on microvilli to facilitate their interaction with endothelial selectins. However, it remains controversial if integrins are similarly localized on microvilli or on the cell body. Regarding the spatial organization of integrins at the cell membrane, there are several studies demonstrating the distribution of LFA-1 in nanoclusters prior to its binding to ligand, at which moment these nanoclusters coalesce into microclusters for efficient adhesion. 32, 33 This avidity regulation of adhesion receptors in leucocytes might be mediated by tetraspanins, as has already been described for VLA-4 34 and some endothelial adhesion receptors. 22 As the leucocyte polarizes during the transition from rolling to firm adhesion, adhesion molecules become segregated to the two cellular poles. L-selectin, CD44, ICAM-3, and ICAM-1, among others, redistribute towards the rear pole (uropod), probably in order to establish an adhesive focus for the recruitment of bystander leucocytes. 35 On the other hand, integrins as LFA-1 and Mac-1 remain at the leading edge. In this regard, it has been shown that Mac-1 molecules are concentrated in microdomains at the front pole of neutrophils, participating in the capture of erythrocytes and platelets, which contributes to inflammatory vascular damage. 36 Once the leucocyte adheres to the apical surface of the endothelial monolayer, it begins to migrate probably following chemotactic gradients originated on the abluminal side of endothelium. 37 This process of leucocyte crawling seems to rely on LFA-1 in lymphocytes, 38 LFA-1, and Mac-1 in monocytes 39 and Mac-1 in neutrophils. 40 Besides, it depends on the endothelial ICAM-1 and ICAM-2. The factors that determine whether leucocytes transmigrate paracellularly at endothelial intercellular junctions or transcellularly through a single cell remain undetermined. However, leucocytes are known to probe for sites suitable for diapedesis by extending 'invadosome-like protrusions' 27 or 'invasive filopodia', 38 and when they find an appropriate place these filopodia progress into an invasive pseudopod that leads the passage of the leucocyte across the cell monolayer.
3. Leucocyte navigation in the inflamed tissue
Migration across the endothelial basement membrane
After transmigration, the leucocytes located underneath the endothelial cell monolayer need to cross the vascular basement membrane, a process that is also tightly regulated. In this regard, there are regions of the venular basement membrane with low matrix protein content, which seem to be preferential sites for neutrophil and monocyte migration following a CCL2 chemotactic gradient. 41, 42 In addition, it has been reported that the mechanism used by each leucocyte subtype is different. Neutrophils are able to enlarge the regions of low protein content by degrading laminin, whereas monocytes can use the pre-existing smaller regions in the basement membrane due to their higher deformability. 41 How lymphocytes behave during this process is still unknown. Apart from neutrophil elastase to degrade laminin, other proteins involved in leucocyte migration across the perivascular basement membrane are a6 integrins and PECAM-1. 43 
Integration of signals by leucocytes
Migrating leucocytes can integrate competing chemoattractant signals, and display memory of their recent environment, allowing them to prioritize newly encountered chemoattractants. 44 Thus, leucocytes are able to discriminate patterns of molecular signals in order to respond adequately in each pathological situation. Interestingly, neutrophils have been found to prioritize signals via PTEN, and as a result respond primarily to bacterial chemoattractants and ignore concomitant inflammatory chemokines. 45 Although it is assumed that diverse leucocyte integrins intervene during the process of extravasation under shear forces, the need for integrins during the subsequent leucocyte interstitial migration is a matter of major debate. 16 Data demonstrating the involvement of b1 integrins such as VLA-2 during neutrophil migration in extravascular tissue 46 contrast with those obtained with leucocytes from mice deficient in all integrin heterodimers, in which interstitial migration does not seem to be affected.
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Environmental cues
In addition to the cell migration signals exposed earlier, there are some environmental factors that contribute to the selective recruitment of inflammatory cells into certain tissues. In this regard, it has been described that external cues as vitamin A from diet and ultraviolet-induced vitamin D3 are able to imprint lymphocyte homing to small intestine and to the epidermis. In addition, bone marrow-derived dendritic cells play an essential role in the transformation of vitamin precursors into their active derivatives such as retinoic acid. These vitamins exert their effects on T lymphocytes during the presentation of antigenic peptides by dendritic cells, affecting their functions. 49 Thus, CCR7 2 memory and effector cells are able to enter into peripheral lymph nodes and migrate into non-lymphoid tissues, where specific chemokines are involved in their recruitment. Cells expressing CCR4, CCR8, and CCR10 and CLA (cutaneous lymphocyte antigen) migrate directly to the skin, whereas the expression of CCR9 and a4b7 integrin directs the migration to the lamina propria. 
Classic and emerging specialized inflammatory subsets
As it has been stated earlier, the differential expression of both cell adhesion molecules and chemokines and their receptors has a key role in the selective recruitment of leucocytes. Thus, after infection by pathogens or during inflammation, myeloid subsets generated in the bone marrow migrate to inflamed non-lymphoid tissues, uptake the antigens and migrate to the lymph nodes. In these organs, it occurs the differentiation of effector and/or Treg cells which up-regulate specific chemokine receptors and migrate to the inflamed tissue. This regulatory mechanism of cell migration is critical to mount a proper immune response in the inflamed tissue with participation of both the innate and adaptive immunity (Figure 2 ).
Relationship of monocytes and dendritic cells and regulation of T cell responses in inflammation
Monocytes, macrophages, and dendritic cells are key regulators of the innate immune response to pathogen infection, and are also central to the development of inflammatory diseases. 50 In addition to classical and alternative activated macrophages, novel subsets of macrophages have been recently identified in mouse and humans. Circulating blood monocytes originate in the bone marrow from a common macrophage/monocyte/DC precursor (MDP), characterized by the phenotype Lin 51 MDP precursor cells also give rise to macrophages, plasmacytoid dendritic cells (pDCs), and conventional spleen DCs (cDCs) (Figure 2 ). These cells have a key function in the differentiation and proliferation of lymphocytes and therefore play an important role in inflammation. In this regard, the migration of monocytes into inflammatory sites and the differentiation of monocytes into DCs have been observed during infection and in inflammatory conditions. However, under certain circumstances, monocytes are able to exert an anti-inflammatory effect. It has been recently reported that in response to ischaemic myocardial injury, spleen monocytes resident in the subcapsular red pulp show a rapid migration to the site of tissue damage, participating in wound healing. 52 Moreover, Ly6C high Gr-1 þ monocytes are able to migrate to different tissue, participating in the mucosal immunity against several pathogens like Toxoplasma gondii. 53 In addition, vascular patrolling CD115 þ Gr1 2 monocytes are able to extravasate to myocardium during infection with Listeria monocytogenes or in the healing myocardium after a myocardial infarction. 54 These monocytes are responsible for an early inflammatory burst, which might contribute to the recruitment of other effector cells. In addition, these monocytes can subsequently differentiate towards alternatively activated macrophages, which might be involved in wound healing. Common DC precursors (CDP) or differentiated subtypes of immature pDCs and cDCs (2) or monocytes and macrophages (3) can re-circulate to maintain the homeostasis or be directed to inflamed non-lymphoid tissues after the upregulation of several chemokine receptors (in brackets) (4) . Once in the inflamed tissue, the innate immune response takes place. Immature DCs uptake the antigen (Ag) (5), mature, and up-regulate the chemokine receptor CCR7 (5) which allow them to migrate via afferent lymphatics to the draining lymph nodes (6) . (B) In the lymph node, mature DCs present the Ag to specific naïve T cells (1), which activate and differentiate into effector Th1, Th2, or Th17 or into Treg (2). Effector CD4 þ T cells, Treg, cytotoxic CD8 þ T cells (CTL), or NK cells up-regulate a pattern of chemokine receptors accounting for driving these cells to the inflamed tissue, then exiting the lymph node via efferent lymphatics (3) to reach inflamed tissue (4) to mount an effective and specialized immune response (5). Therefore, adaptive meets innate immune response at the inflammatory focus.
Dendritic cell development and homeostasis is controlled by the fms-like tyrosine kinase receptor Flt3, which is responsible for the differentiation of DCs from a common bone marrow CX3CR1 þ DC precursor into cDCs and pDCs. 56 Hence, monocytes, macrophages and DCs differentiate from the same CX 3 CR1 þ CD115 þ CD135 þ common precursor, and that the differential expression of chemokine receptors and adhesion molecules is also important for the recruitment of myeloid precursors to different tissues, where these cells may exert important effects. 57 In addition, homeostasis of immune system depends, at least in part, on a feedback regulatory mechanism between DCs and Treg cells. 58 The migration of immature DCs to the non-lymphoid inflamed tissues is dependent on the expression of chemokine receptors such as CCR2, CCR5, and CCR6. After the uptake of the antigens in the inflamed tissue, the expression of these receptors on mature DCs is down-regulated. Then, mature DCs upregulate CCR7 expression, which allows their migration to the lymph nodes and the presentation of antigens to T cells. 59 DCs have a crucial role in the balance of adaptive and innate immunity. In this regard, pDCs can induce tolerance in a model of allergic asthma induced by the administration of OVA directly into the airways of naïve mice. 60 Moreover, pDCs are essential to induce tolerance in vascularized cardiac allografts through the generation of Tregs. 61 
Effector lymphocytes in inflammation
Th1 cells are characterized by the secretion of pro-inflammatory cytokines (e.g. IL-1, TNF-a, and IFN-g) and play an essential role in antiviral responses and bacterial immunity. This subset of T helper cells expresses the chemokine receptors CXCR3, CXCR4, CXCR6, CCR5, CCR7, and CX3CR1 as well as the cell adhesion molecule ICAM-1, and synthesize the chemokine CCL5. 62 -64 It has been found that the expression of CCR5 is critical for the migration of Th1 cells towards inflamed tissues. Moreover, the cytokines IL-12, IL-15, and IL-18 can modulate Th1 responses through the induction of IFN-g, which in turn triggers the synthesis of the pro-inflammatory chemokines CXCL9, CXCL10, and CXCL11. 65 In addition, the expression of adhesion molecules can drive the fate of Th1 cells in response to an inflammatory phenomenon. The adhesion receptor PSGL-1 is expressed at similar levels in Th1 and Th2 cells; however, the binding of this adhesion molecule to P-selectin is important for the recruitment of Th1 cells, and not Th2 cells, to the inflamed skin.
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Th2 cells mainly synthesize IL-4, IL-5, IL-10, and IL-13, and are involved in allergy and immune responses to extracellular pathogens. 67 Th2 cells express the chemokine receptors CCR4, CCR7, CCR8, CXCR4 as well as the prostaglandin D 2 receptor CRTH2 (chemo-attractant receptor homologous molecule expressed in Th2 cells), which is selectively expressed on activated Th2 cells. 62, 68, 69 It has been reported that under certain conditions, the selective expression of CCR8 on Th2 cells accounts for their retention within the inflamed tissue. 68 In addition, the synthesis of Th2 cytokines is enhanced by CCL2 and CXCL4 chemokines. Another subset of effector lymphocytes is the follicular T cells (T FH ). These lymphocytes are characterized for their localization in the follicular areas of B cells, which is mediated by the expression of the chemokine receptor CXCR5 and its ligand CXCL13, secreted by follicular stromal cells. 70 In the B cell follicle, these T FH cells provide a helper function to B cells contributing to antibody responses. In most CD4 þ T cells, CXCR5 is transiently expressed early after activation, and only a small subset of these cells maintains the expression for sufficient time to enable their migration of the follicles. 71 Tregs have a key role in the modulation of the immune response after an inflammatory process or to maintain immune tolerance after antigen elimination, mainly through the inhibition of cytokine synthesis and lymphocyte proliferation. Under steady-state conditions, Tregs cells are mainly localized in the bone marrow, due to their expression of the chemokine receptor CXCR4. Under inflammatory conditions, Treg cells are able to migrate to the areas of tissue damage, a phenomenon that is mediated by the chemokine receptors CXCR3, CCR2, CCR4, CCR5, and CCR6. 72 In this regard, it has been described that the expression of CCR2 by T cells allows their recruitment to the inflamed joints in an animal model of rheumatoid arthritis, and that these cells exert a regulatory function. 73 Moreover, it has been recently reported that CCR7 is involved in both the migratory behaviour of Tregs to the skin in a model of contact dermatitis and to the small intestine in a model of inflammatory bowel disease in mice. 74 In addition to the classical Th1, Th2, T follicular helper cells (T FH ), and regulatory T cells (Tregs), the characterization of the Th17 pro-inflammatory subset, has changed the general scheme of the effector responses in inflammatory conditions. 75 -77 receptors CCR9, a4b7 integrin and the a E subunit of the a E b7 integrin (CD103). 79 Resting human Th17 cells express CCR2, CXCR4, CXCR6, and CCR4, and are the only subset of memory cells which express persistent high levels of CCR6 after activation. CCR6 expression by Th17 cells is essential for the migration of these cells to the inflamed tissue. 80 This highly pro-inflammatory population has an important role in the pathogenesis of different autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and asthma. 81 In addition, it has been found that Th17 cells are also involved in the pathogenesis of tissue damage and vasculopathy associated to allograft rejection. 82 Moreover, some subsets of Th17 cells are also able to release IFN-g, and this cytokine exerts a synergistic effect with IL-17 on the induction of vascular inflammation. 83 However, it has been recently reported that under certain conditions, IL-17 may exert an antiinflammatory effect, diminishing vascular inflammation and the development of the atherosclerotic lesions. 84 New effector T cell subsets continue to be defined and, in this regard, TGF-b 'reprograms' Th2 cells to lose their characteristic profile and switch to IL-9 secretion. 85 This 'Th9' subset can exert a pro-inflammatory effect, and favours Th17 cell differentiation. In addition, it has recently been identified an IL-22-producing human helper T cell population that co-expressed the chemokine receptors CCR6, CCR4, and CCR10 as a functionally distinct subset that can be involved in skin inflammation. 86, 87 Cytotoxic CD8 þ T cells are crucial for the development of adaptive immune responses to virus infection and tumour growth. 
Future therapeutic perspectives
Understanding the plethora of cues from multiple sources that leucocytes detect and integrate during their journey to every kind of inflammatory scenario is of critical importance in the search of novel therapeutic targets in inflammatory and autoimmune conditions. Antiinflammatory therapies based on the use of monoclonal antibodies or small antagonist directed against key adhesion receptors [selectins, 90 integrins, and their ligands (a4b7 in gut 91 ), cytokines (TNF-a, 92 IFN-g, 93 IL1, 94 IL-12/23 95 ), or chemokines (anti-CCL27 in skin, 96 anti-CCL5 in atherosclerosis 97 )] tend to resolve inflammation by limiting the amount of leucocytes recruited to inflamed tissue and are effective in different animal models as well as some of them in humans. In the case of leucocyte integrins VLA-4 and LFA-1, humanized monoclonal antibodies generated against them have been already successfully employed in the clinical practice. 98, 99 Thus,
anti-a4 has shown a clear therapeutic effect in the relapsing form of multiple sclerosis 100 and in Crohn's disease, 101 whereas anti-LFA-1 in plaque-type psoriasis. 102 However, as these therapeutic agents are directed against receptors with a wide range of different immune functions apart from extravasation, their long-term administration may have undesirable effects (reviewed by Gonzalez-Amaro et al. 103 ). In this regard, the administration of anti-a4 has been associated with cases of progressive multifocal leucoencephalopathy, and the therapy with anti-TNF-a agents significantly enhances the risk for tuberculosis reactivation. 104 Other promising new anti-inflammatory targets are tetraspanins, 105 since these proteins simultaneously regulate the avidity of multiple adhesion receptors in the plasma membrane of endothelial cells and possibly also in leucocytes. Therefore, inhibition of a specific tetraspanin might prove to be a more effective strategy than the inhibition of a single-type adhesion molecule. In this regard, the endothelial tetraspanin CD81 has been proposed as a diagnostic marker of early atherogenesis in humans. Indeed, it has been described its crucial role at the early stages of atheroma formation, being a potential therapeutic target for this condition, 106 as well as for EAE amelioration. 107 Finally, cellular therapies based on mesenchymal and hematopoietic stem cells, DCs and Tregs arise as promising future anti-inflammatory approaches due to the immunoregulatory properties of these subsets in diverse inflammatory pathologies.
